Showing 4111-4120 of 10627 results for "".
Family Planning Clinical Considerations for Patients with Multiple Sclerosis
https://reachmd.com/programs/neurofrontiers/family-planning-clinical-considerations-for-patients-with-multiple-sclerosis/18044/What family planning considerations should be made for our multiple sclerosis patients? Here’s what you need to know.Investigating Gene Therapy for DMD: The Role of Caregiver-Reporter Scales
https://reachmd.com/programs/neurofrontiers/investigating-gene-therapy-for-dmd-the-role-of-caregiver-reporter-scales/32359/Hear how researchers can use caregiver-reported scales to analyze gene therapy outcomes in Duchenne muscular dystrophy patients.Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
https://reachmd.com/programs/cme/breaking-new-ground-acoramidis-reduces-af-events-in-attr-cm-patients-from-esc-heart-failure-2025/36590/Review data from ESC Heart Failure 2025 on acoramidis and its association with reduced atrial fibrillation and improved outcomes in ATTR-CM.The Diagnostic Journey of IgA Nephropathy: Identifying Key Obstacles
https://reachmd.com/programs/frontlines-iga-nephropathy/the-diagnostic-journey-of-iga-nephropathy-identifying-key-obstacles/26947/What are the most common challenges in diagnosing IgA nephropathy? Tune in to find out.ASCO GU 2024: Reviewing Updated Practice Guidelines for Prostate Cancer
https://reachmd.com/programs/project-oncology/asco-gu-2024-reviewing-updated-practice-guidelines-for-prostate-cancer/17879/This session from ASCO GU Symposium 2024 reviews updated practice guidelines for prostate cancer. Listen now.BCMA mRNA CAR-T Shows Durable Benefit in MG
https://reachmd.com/programs/neurofrontiers/bcma-mrna-car-t-shows-durable-benefit-in-mg/51012/Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
https://reachmd.com/clinical-practice/oncology-hematology/cohort-9-of-the-phase-2-ev-202-trial-first-line-enfortumab-vedotin-plus-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma/39779/In cohort 9 of EV-202, first-line enfortumab vedotin plus pembrolizumab showed promising and durable responses in patients with recurrent or metastatic HNSCC.The Lingering Impact of Covid-19
https://reachmd.com/programs/what-your-patients-are-talking-about/tbd/15487/What is immunity gap? Tune in.Unmet Needs in Rehabilitation Research for Multiple Sclerosis
https://reachmd.com/programs/neurofrontiers/unmet-needs-in-rehabilitation-research-for-multiple-sclerosis/18040/What are the current unmet needs in rehabilitation research for MS? Tune in.New Consensus for Smoldering Disease in MS
https://reachmd.com/programs/neurofrontiers/new-consensus-for-smoldering-disease-in-ms/16270/Read more on new research on smoldering disease in MS that was presented at the 2023 ECTRIMS-ACTRIMS.